TMCI Relative Valuation
TMCI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMCI is overvalued; if below, it's undervalued.
Historical Valuation
Treace Medical Concepts Inc (TMCI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -31.61. The fair price of Treace Medical Concepts Inc (TMCI) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.68 USD , Treace Medical Concepts Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：2.68
Fair
Undervalued
-3.22
PE
1Y
3Y
5Y
Trailing
Forward
-37.12
EV/EBITDA
Treace Medical Concepts Inc. (TMCI) has a current EV/EBITDA of -37.12. The 5-year average EV/EBITDA is 35.04. The thresholds are as follows: Strongly Undervalued below -956.09, Undervalued between -956.09 and -460.52, Fairly Valued between 530.60 and -460.52, Overvalued between 530.60 and 1026.16, and Strongly Overvalued above 1026.16. The current Forward EV/EBITDA of -37.12 falls within the Historic Trend Line -Fairly Valued range.
-3.58
EV/EBIT
Treace Medical Concepts Inc. (TMCI) has a current EV/EBIT of -3.58. The 5-year average EV/EBIT is -40.03. The thresholds are as follows: Strongly Undervalued below -146.81, Undervalued between -146.81 and -93.42, Fairly Valued between 13.36 and -93.42, Overvalued between 13.36 and 66.75, and Strongly Overvalued above 66.75. The current Forward EV/EBIT of -3.58 falls within the Historic Trend Line -Fairly Valued range.
0.81
PS
Treace Medical Concepts Inc. (TMCI) has a current PS of 0.81. The 5-year average PS is 5.77. The thresholds are as follows: Strongly Undervalued below -2.28, Undervalued between -2.28 and 1.75, Fairly Valued between 9.80 and 1.75, Overvalued between 9.80 and 13.82, and Strongly Overvalued above 13.82. The current Forward PS of 0.81 falls within the Undervalued range.
-6.63
P/OCF
Treace Medical Concepts Inc. (TMCI) has a current P/OCF of -6.63. The 5-year average P/OCF is -43.02. The thresholds are as follows: Strongly Undervalued below -93.14, Undervalued between -93.14 and -68.08, Fairly Valued between -17.96 and -68.08, Overvalued between -17.96 and 7.10, and Strongly Overvalued above 7.10. The current Forward P/OCF of -6.63 falls within the Overvalued range.
-5.84
P/FCF
Treace Medical Concepts Inc. (TMCI) has a current P/FCF of -5.84. The 5-year average P/FCF is -34.62. The thresholds are as follows: Strongly Undervalued below -79.77, Undervalued between -79.77 and -57.19, Fairly Valued between -12.05 and -57.19, Overvalued between -12.05 and 10.52, and Strongly Overvalued above 10.52. The current Forward P/FCF of -5.84 falls within the Overvalued range.
Treace Medical Concepts Inc (TMCI) has a current Price-to-Book (P/B) ratio of 1.91. Compared to its 3-year average P/B ratio of 6.93 , the current P/B ratio is approximately -72.36% higher. Relative to its 5-year average P/B ratio of 2.95, the current P/B ratio is about -35.07% higher. Treace Medical Concepts Inc (TMCI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -7.37%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -5.46% , the current FCF yield is about -100.00% lower.
1.96
P/B
Median3y
6.93
Median5y
2.95
-15.43
FCF Yield
Median3y
-7.37
Median5y
-5.46
Competitors Valuation Multiple
The average P/S ratio for TMCI's competitors is 6.32, providing a benchmark for relative valuation. Treace Medical Concepts Inc Corp (TMCI) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 11.37%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TMCI decreased by 63.17% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 45.09M to 50.21M.
The secondary factor is the Margin Expansion, contributed -4.78%to the performance.
Overall, the performance of TMCI in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Treace Medical Concepts Inc (TMCI) currently overvalued or undervalued?
What is Treace Medical Concepts Inc (TMCI) fair value?
How does TMCI's valuation metrics compare to the industry average?
What is the current P/B ratio for Treace Medical Concepts Inc (TMCI) as of Dec 05 2025?
What is the current FCF Yield for Treace Medical Concepts Inc (TMCI) as of Dec 05 2025?
What is the current Forward P/E ratio for Treace Medical Concepts Inc (TMCI) as of Dec 05 2025?